Advanced gene editing technologies can be implemented successfully for the improvement of drug discovery disease models and assay development.
Single-guided RNA CRISPR technologies create unwanted off-target mutations that may derail research investments. Many of these technologies have also been hampered by intellectual property entanglements and restrictive licensing. This article introduces our Cas-CLOVER gene editing technology, which is a dimeric guide system, free of detectable off-targets and licensing impediments “the clean alternative to CRISPR/Cas9”. It is our mission to make this technology readily available in the discovery research space through services and accessible licensing with freedom to operate.
Offered Free by: HeraBiolabs
See All Resources from: HeraBiolabs
This download should complete shortly. If the resource doesn't automatically download, please, click here.